COVID-19与流感肺炎插管患者早期细菌鉴定:欧洲多中心比较临床试验
该欧洲多中心回顾性队列纳入36个ICU中插管超过48小时的COVID-19或流感肺炎成人患者,比较插管后48小时内细菌鉴定阳性率。COVID-19组细菌鉴定阳性率显著低于流感组(9.7% vs 33.6%),且细菌鉴定与COVID-19患者28天死亡率升高相关。
要点
- 插管后48小时内细菌鉴定阳性率COVID-19组9.7%,显著低于流感组33.6%。
- 两组共感染均以革兰阳性球菌为主,分别占58%和72%。
- COVID-19组细菌鉴定与28天死亡率升高相关(调整HR 1.57)。
核心结论
- 插管后48小时内细菌鉴定在SARS-CoV-2肺炎患者中显著少于流感肺炎患者。
- 细菌鉴定与SARS-CoV-2肺炎患者28天死亡率升高相关,但两组间该影响无显著异质性。
研究设计与样本
- 欧洲36个ICU的多中心回顾性队列研究。
- 纳入ICU admission时患SARS-CoV-2或流感肺炎且接受有创机械通气>48小时的成人患者,共1050例(SARS-CoV-2组568例,流感组482例)。
- 细菌鉴定定义为插管后48小时内气管吸引物、BAL、血培养阳性或肺炎链球菌/军团菌尿抗原阳性。
主要发现
- 细菌鉴定阳性率SARS-CoV-2组9.7%,流感组33.6%(未调整OR 0.21,95%CI 0.15-0.30;调整OR 0.23,95%CI 0.16-0.33;P<0.0001)。
- 革兰阳性球菌占SARS-CoV-2组共感染的58%,占流感组的72%。
- SARS-CoV-2组细菌鉴定与28天死亡率升高相关(调整HR 1.57,95%CI 1.01-2.44,P=0.043)。
- 两组间与细菌鉴定相关结局的异质性无显著差异。
临床怎么用
- 对于插管COVID-19肺炎患者,早期细菌共感染率低于流感肺炎患者,应结合临床审慎评估经验性抗菌治疗。
- 插管后48小时内检出细菌与COVID-19患者预后较差相关,需关注并管理共感染。
局限性
- 为回顾性队列研究设计。
- 细菌鉴定定义限于插管后48小时内,可能低估后续感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Early empirical antimicrobial treatment is frequently prescribed to critically ill patients with coronavirus disease (COVID-19) based on Surviving Sepsis Campaign guidelines.Objectives: We aimed to determine the prevalence of early bacterial identification in intubated patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia, as compared with influenza pneumonia, and to characterize its microbiology and impact on outcomes.Methods: A multicenter retrospective European cohort was performed in 36 ICUs. All adult patients receiving invasive mechanical ventilation >48 hours were eligible if they had SARS-CoV-2 or influenza pneumonia at ICU admission. Bacterial identification was defined by a positive bacterial culture within 48 hours after intubation in endotracheal aspirates, BAL, blood cultures, or a positive pneumococcal or legionella urinary antigen test.Measurements and Main Results: A total of 1,050 patients were included (568 in SARS-CoV-2 and 482 in influenza groups). The prevalence of bacterial identification was significantly lower in patients with SARS-CoV-2 pneumonia compared with patients with influenza pneumonia (9.7 vs. 33.6%; unadjusted odds ratio, 0.21; 95% confidence interval [CI], 0.15-0.30; adjusted odds ratio, 0.23; 95% CI, 0.16-0.33; P < 0.0001). Gram-positive cocci were responsible for 58% and 72% of coinfection in patients with SARS-CoV-2 and influenza pneumonia, respectively. Bacterial identification was associated with increased adjusted hazard ratio for 28-day mortality in patients with SARS-CoV-2 pneumonia (1.57; 95% CI, 1.01-2.44; P = 0.043). However, no significant difference was found in the heterogeneity of outcomes related to bacterial identification between the two study groups, suggesting that the impact of coinfection on mortality was not different between patients with SARS-CoV-2 and influenza.Conclusions: Bacterial identification within 48 hours after intubation is significantly less frequent in patients with SARS-CoV-2 pneumonia than patients with influenza pneumonia.Clinical trial registered with www.clinicaltrials.gov (NCT04359693).
引用
- Rouzé A, Martin-Loeches I, Povoa P, et al. Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial. Am J Respir Crit Care Med. 2021. PMID: 34038699. doi:10.1164/rccm.202101-0030OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。